Clinical trials: Diabetic Nephropathy Type 2
Chronic Kidney Diseases, Diabetic Kidney Disease
Real World Evidence Clinical Utility Study of KidneyIntelX
The purpose of this study is to assess the impact of the KidneyIntelX assay utilized as part of the current standard of care on the management of patients seen in the primary care physician's office at Mount Sinai.
- Trial name
- NCT04802395
- Testing
- KidneyIntelX
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Renalytix AI, Inc.
Diabetic Nephropathy Type 2
Impact of Dapagliflozin as Add-on Therapy on Glycemic Status and Quality of Life in Type 2 Diabetic Patients
Type 2 Diabetes Mellitus (T2DM) is a syndrome of metabolic dysregulation that needs a multifactorial behavioral and pharmacological treatments to prevent or delay complications, morbidity and mortality.
- Trial name
- NCT06326034
- Testing
- Dapagliflozin
- Where
- Iraq
- Volunteers
- 40 people
- Sponsor
- Mohammed Mahmood Mohammed
Diabetic Nephropathy, Type 2 Diabetes Mellitus
ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial
The purpose of the study is to evaluate the effectiveness and safety of olmesartan versus placebo on the progression of diabetic renal disease.
- Conditions
- Diabetic Nephropathy, Type 2 Diabetes Mellitus, Proteinuria
- Trial name
- NCT00141453
- Testing
- olmesartan medoxomil
- Where
- 2 sites in China, Japan
- Volunteers
- 577 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Diabetes Mellitus, Type 2, Liver Diseases
Validate Smart Breath Analyzer as Screening Tool for Diabetic, Hepatic, Renal, Lung, and Other Metabolic Disorders
This is a prospective, multicentric, non-treatment study to build and validate a portable, non-invasive smart breath analyzer that can screen underlying health issues using exhaled breath.
- Conditions
- Diabetes Mellitus, Type 2, Liver Diseases, Kidney Diseases, Lung Diseases
- Trial name
- RESPYR-SBA (NCT07646015)
- Where
- India
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Respyr
Type 1 Diabetes, Nephropathy, Diabetic
SGLT2 Adjunct in T1D
Effect of Sodium-Glucose Cotransporter (SGLT) 2 Inhibitors on Diabetic Nephropathy Progression in Adolescents with Type 1 Diabetes Mellitus
- Trial name
- NCT07591077
- Testing
- Empagliflozin (EMPA)
- Where
- Egypt
- Volunteers
- 86 people
- Sponsor
- Ain Shams University
Diabetic Kidney Disease, Diabetes Mellitus, Type 2
EMPRA (EMPagliflozin and RAs in Kidney Disease)
This study will be a prospective, clinical pilot study in CKD patients to show whether Empagliflozin in addition to ACEi treatment significantly increases Ang 1-7 levels compared to ACEi treatment alone.
- Conditions
- Diabetic Kidney Disease, Diabetes Mellitus, Type 2, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
- Trial name
- EMPRA (NCT03078101)
- Testing
- Empagliflozin 10 MG [Jardiance]
- Where
- Austria
- Volunteers
- 51 people
- Sponsor
- Medical University of Vienna
Diabetes Mellitus, Coronary Artery Bypass
Remote Ischemic Preconditioning in Type 2 Diabetic Patients Undergoing CABG
This randomized, double-blind, prospective clinical trial aims to investigate the effect of remote ischemic preconditioning (RIPC) on myocardial protection in patients with type 2 diabetes mellitus undergoing elective coronary…
- Conditions
- Diabetes Mellitus, Coronary Artery Bypass, Remote Ischaemic Conditioning
- Trial name
- NCT06977230
- Testing
- Remote Ischemic Preconditioning
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Muğla Sıtkı Koçman University
Type 2 Diabetes Mellitus, Diabetic Nephropathy
Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy
The purpose of this study is to evaluate the effect of FG-3019 on diabetic kidney disease or diabetic nephropathy.
- Conditions
- Type 2 Diabetes Mellitus, Diabetic Nephropathy, Diabetic Kidney Disease
- Trial name
- NCT00913393
- Testing
- FG-3019
- Where
- 28 sites in United States
- Volunteers
- 46 people
- Sponsor
- Kyntra Bio
Chronic Kidney Disease, Diabetic Nephropathy
Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor
Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Study. The objective of the study is to evaluate the efficacy and safety of once daily administration of atrasentan tablets (low dose and high dose) compared…
- Trial name
- RADAR (NCT01356849)
- Testing
- Atrasentan
- Where
- 72 sites in United States, Canada and 2 more
- Volunteers
- 149 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
End-Stage Kidney Disease, Type 2 Diabetes Mellitus
Glucose Containing and Glucose Free Hemodialysate in Type 2 Diabetic Patients
The purpose of this study is to investigate differences in glycemia during the whole hemodialysis day and the whole freeday during hemodialysis, during the evening and the night after hemodialysis and at the same time intervals…
- Trial name
- NCT02009514
- Testing
- Glucose-containing compared to glucose-free hemodialysate
- Volunteers
- 10 people
- Sponsor
- Tampere University Hospital
Type 2 Diabetes, Diabetic Kidney Disease
Mechanism of SGLT2 Inhibition in the Kidney
The goal of this open-label, non-randomized clinical trial is to determine what effects, if any, an FDA-approved drug class known as SGLT2 inhibitors (Canagliflozin or INVOKANA) has any protective effects on kidney function in…
- Trial name
- NCT06291155
- Testing
- SGLT2 inhibitor
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Michigan
Diabetic Kidney Disease, Type 2 Diabetes
Efficacy and Safety of HRS-7535 Tablets in Adults With Diabetic Kidney Disease in Type 2 Diabetes
The study is a 16-week multicenter, randomized, double-blind, placebo-controlled, parallel-designed Phase II clinical study. The aim of this trial is to evaluate the efficacy and safety of HRS-7535 in subjects with diabetic…
- Trial name
- SOLID-DKD (NCT06415214)
- Testing
- HRS-7535
- Where
- China
- Volunteers
- 281 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Chronic Kidney Disease
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
The primary objective of this study was to demonstrate whether, in addition to standard of care, finerenone is superior to placebo in delaying the progression of kidney disease, as measured by the composite endpoint of time to…
- Trial name
- FIDELIO-DKD (NCT02540993)
- Testing
- Finerenone (BAY94-8862)
- Where
- 978 sites in United States, Argentina and 46 more
- Volunteers
- 5,734 people
- Sponsor
- Bayer
Type 2 Diabetes With Renal Manifestations
Predictors of Chronic Kidney Disease Among Type 2 Diabetic Patients in Assiut University Hospitals
Predictors of Chronic Kidney Disease among Type 2 Diabetic Patients in Assiut University Hospitals.
- Trial name
- Ckd&dm (NCT05847400)
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Assiut University
Type 2 Diabetes (T2DM), Diabetic Nephropathies
A Multicenter Randomized Double-Blind Trial of Chrocare CDSS for Integrated Management of Type 2 Diabetes
This is a multicenter, randomized, double-blind, parallel-group clinical study for adults with type 2 diabetes and early diabetic kidney or retinal complications.
- Conditions
- Type 2 Diabetes (T2DM), Diabetic Nephropathies, Diabetic Retinopathy (DR)
- Trial name
- Chrocare-DM (NCT07833228)
- Testing
- AI large language model-based clinical decision support system, Standard diabetes integrated management formulated by endocrinologists
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Type 2 Diabetes Mellitus, Inflammation, Chronic Low-Grade
Lifestyle Intervention and Its Effects on Inflammatory Cytokines and Oxidative Stress Markers in Diabetic Chronic Kidney Disease Patients: A Randomized Controlled Trial
This randomized controlled trial investigated the effects of a 12-week structured lifestyle intervention-including supervised aerobic exercise and a calorie-restricted diet-on inflammatory cytokines and oxidative stress…
- Conditions
- Type 2 Diabetes Mellitus, Inflammation, Chronic Low-Grade, Chronic Kidney Disease, Stage 3 Chronic Kidney Disease
- Trial name
- Lifestyle Inte (NCT07119892)
- Testing
- Lifestyle Modification (Exercise + Diet)
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Sinai University
Chronic Kidney Diseases, Diabetes Mellitus
Prevalence of Chronic Kidney Disease in Tunisian Diabetics
In Tunisia, diabetes is a serious public health problem, its prevalence reaches 22.9% of people aged 18 and over and is likely to affect a quarter of the population by 2045.
- Conditions
- Chronic Kidney Diseases, Diabetes Mellitus, Diabetes Type 2
- Trial name
- TUN-CKDD (NCT05577650)
- Where
- Tunisia
- Volunteers
- 10,145 people
- Sponsor
- Dacima Consulting
Diabetes Mellitus, Type 2, Diabetic Nephropathies
Nutritional Outcomes of Lotus Seed (Nelumbo Nucifera) on Diabetic Sensorimotor Polyneuropathy
The study focuses on Diabetic Sensorimotor Polyneuropathy (DSPN), a common complication of type 1 and type 2 diabetes caused by hyperglycemia-induced nerve damage, leading to pain, numbness, and motor dysfunction in the limbs.
- Trial name
- NCT06778018
- Testing
- Lotus Seed
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Riphah International University
Type 2 Diabetes Mellitus, Diabetic Nephropathy
Olmesartan Medoxomil and Diabetic Nephropathy
Evaluation of several olmesartan dosages compared to losartan on proteinuria, renal function and inflammatory markers in patients with diabetic nephropathy
- Conditions
- Type 2 Diabetes Mellitus, Diabetic Nephropathy, Proteinuria, Renal Disease
- Trial name
- NCT00362960
- Testing
- Olmesartan medoxomil, Losartan
- Where
- 27 sites in Czechia, Estonia and 5 more
- Volunteers
- 300 people
- Sponsor
- Sankyo Pharma Gmbh
Type 2 Diabetes Mellitus, Obesity
The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes
This research study is being performed to begin to determine the effectiveness of two dominant bariatric surgery procedures versus an intensive lifestyle intervention to induce weight loss in patients and promote improvements in…
- Trial name
- TRIABETES (NCT01047735)
- Testing
- Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- University of Pittsburgh